This article provides an update on the genetics, clinical features, natural history, and management of Facioscapulohumeral Dystrophy to increase clinical awareness.
Answers are grounded in this paper and cite their sources.
May enhance FSHD recognition in practice; leaves open prospective validation of management updates.
Facioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy. Over the last decade, major advances have occurred in the understanding of the genetics of this disorder. Despite these advances, the exact mechanisms that lead to atrophy and weakness secondary to the genetic defect are still not understood. The purposes of this article are to increase awareness of FSHD among clinicians; to provide an update regarding the genetics, clinical features, natural history, and current management of FSHD; and to discuss opportunities for research.
No takes yet. Share an insight, caveat, or question.
Pandya et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: